NEW YORK, August 6, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports
highlighting Gilead Sciences Inc. (NYSE: GILD), Celgene Corporation
(NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), and Amgen Inc. (NASDAQ:
AMGN). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings
- via the links below.
Gilead Sciences Inc. Research
Report
On July 25, 2013, Gilead Sciences
Inc. (Gilead) released its Q2 2013 financial results. The Company
reported total revenues of $2.8
billion, up 15.1% YoY, as product sales increased 14.7% YoY
to $2.7 billion, driven primarily by
growth in Gilead's antiviral franchise, in Q2 2013. On the other
hand, royalty, contract, and other revenues were up31.2% YoY to
$110.1 million. Net income
attributable to the Company was up 8.6% YoY to $772.6 million, while diluted EPS in Q2 2013
remained unchanged at $0.46 from Q2
2012. The Full Research Report on Gilead Sciences Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-02/GILD]
--
Celgene Corporation Research
Report
On August 1, 2013, Celgene
Corporation (Celgene) announced its intention to offer senior
unsecured notes under a shelf registration statement on Form S-3 on
file with the Securities and Exchange Commission, subject to market
and other conditions. Celgene reported that the interest rate, the
maturity dates, and other key terms of the offering will be
determined at the time of pricing. The Company stated that it
intends to use the net proceeds from the offering for general
corporate purposes, which may include, without limitation, further
development of Celgene's clinical and pre-clinical programs,
capital expenditures, general corporate development activities,
meeting working capital needs, share repurchases of common stock,
and repayment of some or all of its outstanding commercial papers.
The Full Research Report on Celgene Corporation - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-02/CELG]
--
Onyx Pharmaceuticals, Inc. Research
Report
On July 31, 2013, Onyx
Pharmaceuticals, Inc. (Onyx Pharmaceuticals) announced that it will
release its Q2 2013 financial results after the market closes on
Thursday, August 8, 2013. Onyx
Pharmaceuticals reported that it will hold a webcast and conference
call with the financial community for the discussion of its Q2 2013
financial results and general business overview on the same day at
5:00 p.m. ET (2:00 p.m. PT). The Full Research Report on Onyx
Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge
at: [http://www.InvestorsReports.com/report/2013-08-02/ONXX]
--
Questcor Pharmaceuticals, Inc.
Research Report
On July 30, 2013, Questcor
Pharmaceuticals, Inc. (Questcor) released its Q2 2013 financial
results. The Company reported that its net income was up 66.5% YoY
to $69.1 million, and diluted EPS was
up 72.3% YoY to $1.12, during the
quarter. Net sales were up 64.1% YoY to $184.6 million, primarily attributable to the
expanded usage of H.P. Acthar Gel (repository corticotropin
injection) by rheumatologists in the treatment of patients
suffering from dermatomyositis; polymyositis; systemic lupus
erythematosus; and rheumatoid arthritis, besides the growth of
nephrological and neurological prescriptions for the treatment of
nephrotic syndrome (NS) and multiple sclerosis (MS) relapses and
infantile spasms (IS), respectively. Steve
Cartt, Chief Operating Officer of Questcor, stated, "Total
new paid prescriptions for Acthar were approximately 2,250 to 2,275
in the second quarter, an increase of about 35% year-over-year."
The Full Research Report on Questcor Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-02/QCOR]
--
Amgen Inc. Research Report
On July 30, 2013, Amgen Inc.
(Amgen) released its Q2 2013 financial results. The Company's
revenues were up 4.5% YoY to $4.7
billion, as total product sales increased 9.4% YoY to
$4.6 billion, driven by Enbrel
(etanercept), Neulasta (pegfilgrastim), XGEVA (denosumab), and
Prolia (denosumab), during the quarter. Net income was down 0.6%
YoY to $1.3 million, and diluted EPS
was up 2.5% YoY to $1.65.
Robert A. Bradway, Chairman and CEO
of Amgen, said, "We saw solid product trends during the second
quarter and are carrying good momentum into the second half."
Bradway added, "We continue to make excellent progress with our
pipeline of innovative molecules and look forward to multiple data
readouts in 2014, including pivotal Phase 3 data for our
cholesterol-lowering agent, AMG 145, in the first quarter." For
full-year 2013, Amgen expects revenues to be at the upper end of
$17.8 billion to $18.2 billion;
adjusted EPS to be in the range of $7.30 to
$7.45; adjusted tax rate to be in the range of 9% to 10%;
and capital expenditures to be approximately $700 million. The Full Research Report on Amgen
Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-02/AMGN]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
SOURCE Investors' Reports